Investigational Drug Information for PSN-632,408
✉ Email this page to a colleague
What is the development status for investigational drug PSN-632,408?
PSN-632,408 is an investigational drug.
There have been 7 clinical trials for PSN-632,408.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Neurotoxicity Syndromes, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are Sanofi, Attikon Hospital, and National Cheng-Kung University Hospital.
There are sixty-four US patents protecting this investigational drug and seven hundred and thirty-seven international patents.
Summary for PSN-632,408
| US Patents | 64 |
| International Patents | 737 |
| US Patent Applications | 113 |
| WIPO Patent Applications | 62 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2020-07-01) |
| Vendors | 31 |
Recent Clinical Trials for PSN-632,408
| Title | Sponsor | Phase |
|---|---|---|
| Topical Vancomycin Over Sternal Edge in Cardiac Surgery | National Cheng-Kung University Hospital | Phase 4 |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Alberta | N/A |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Toronto | N/A |
Clinical Trial Summary for PSN-632,408
Top disease conditions for PSN-632,408
Top clinical trial sponsors for PSN-632,408
US Patents for PSN-632,408
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PSN-632,408 | See Plans and Pricing | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | See Plans and Pricing |
| PSN-632,408 | See Plans and Pricing | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | See Plans and Pricing |
| PSN-632,408 | See Plans and Pricing | Substituted piperidines having GPR119 agonistic activity | DONG-A ST CO., LTD. (KR) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PSN-632,408
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PSN-632,408 | Argentina | AR091089 | 2031-01-07 | See Plans and Pricing |
| PSN-632,408 | Argentina | AR091739 | 2031-01-07 | See Plans and Pricing |
| PSN-632,408 | Australia | AU2011317140 | 2030-10-19 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
